Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

Connie L. Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, John F. Gerecitano, Paul A. Hamlin, Steve M. Horwitz, Erel Joffe, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Ariela Noy, Colette Owens, Lia M. Palomba, David Straus, Gottfried von Keudell, Andrew D. ZelenetzVenkatraman E. Seshan, Stefano Luminari, Luigi Marcheselli, Massimo Federico, Anas Younes

Research output: Contribution to journalArticle

Abstract

Background: Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD. Methods: In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis evaluated the association between early POD and histologic transformation. Results: In the discovery cohort, patients with POD within 24 months (PFS24) of initiating R-CHOP therapy had a 5-year OS of 57.6% for CT-staged patients compared with 70.6% for PET-staged patients. In the validation cohort, the 5-year OS for patients with early POD was 53.9% and 100% in CT- and PET-staged patients, respectively. The risk of histologic transformation in patients whose disease progressed within one year of initiating therapy was higher in CT-staged patients than in PET-staged patients (16.7% versus 6.3%, respectively), which was associated with a 9.7-fold higher risk of death. Conclusion: In FL, pre-treatment PET staging reduced the prognostic impact of early POD compared with CT staging. Patients with early POD and no histologic transformation have an extended OS with standard therapy.

Original languageEnglish (US)
Pages (from-to)78-90
Number of pages13
JournalEuropean Journal of Cancer
Volume126
DOIs
StatePublished - Feb 2020
Externally publishedYes

    Fingerprint

Keywords

  • Early progression
  • Follicular lymphoma
  • PET
  • PFS24
  • R-CHOP

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Batlevi, C. L., Sha, F., Alperovich, A., Ni, A., Smith, K., Ying, Z., Gerecitano, J. F., Hamlin, P. A., Horwitz, S. M., Joffe, E., Kumar, A., Matasar, M. J., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Owens, C., Palomba, L. M., Straus, D., von Keudell, G., ... Younes, A. (2020). Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. European Journal of Cancer, 126, 78-90. https://doi.org/10.1016/j.ejca.2019.12.006